Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse

International Journal of Cancer

Volumn 108, Issue 4, 2004, Pages 620-627

  Giatromanolaki, Alexandra ^a   Koukourakisi, Michael I ^a   Kakolyris, Stelios ^b   Mavroudis, Dimitris ^b   Kouroussis, Charalambos ^b   Mavroudi, Chrysa ^b   Perraki, Maria ^b   Sivridis, Efthimios ^a   Georgoulias, Vassilis ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiogenesis; Breast cancer; Cytokeratin 19; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ANALYTIC METHOD; ANGIOGENESIS; ARTICLE; BIOACCUMULATION; BLOOD DISEASE; BREAST CARCINOMA; CANCER CELL; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DISSEMINATED CANCER; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARD;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KERATINS; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0347417894     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11593     Document Type: Article

References (47)

1. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage 1, II, or III breast cancer. N Engl J Med 2000;342:525-33.
2. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Basten G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8.
3. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24.
4. Mathieu MC, Friedman S, Bosq J, Caillou B, Spielmann M, Travagli JP, Contesso G. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat 1990;15:21-6.
5. Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, Dimpfl T, Sommer H, Braun S. Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 2000;88:2252-9.
6. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-9.
7. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994;69:566-71.
8. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Corrincione CT, Budman DR, Wood WC, Bacros M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node positive breast cancer. N Engl J Med 1994;330:1308-9.
9. Tokuda Y, Ohta M, Suzuki Y, Kubota M, Tajima T. Clinical development of trastuzumab in breast cancer. Breast Cancer 2001;8:93-7.
10. Leek R. Prognostic role of angiogenesis in breast cancer. Anticancer Res 2001;21:4325-31.
11. Kakolyris S, Fox SB, Koukourakis MI, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis using a novel basement membrane epitope, LH39. Br J Cancer 2000;82:844-51.
12. Konerding MA, Malkusch W, Klapthor B, van Ackern C, Fait E, Hill SA, Parkins C, Chaplin DJ, Presta M, Denekamp J. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 1999;80:724-32.
13. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001;21:4285-300.
14. Mattern J. Role of angiogenesis in drug resistance. Anticancer Res 2001;21:4265-70.
15. McCarthy N, Swain S. Update on adjuvant chemotherapy for early breast cancer. Oncology 2000;14:1267-80.
16. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot D, Harris AL, Gatter KC. Angiogenesis is a significant prognostic marker in operable non small cell lung cancer. J Pathol 1996;179:80-8.
17. Giatromanolaki A, Koukourakis M, Theodossiou D, Barbatis C, Harris AL, Gatter KC. Comparative evaluation of angiogenesis assessment with anti-Factor VIII and anti-CD31 immunostaining in non small cell lung cancer. Clin Cancer Res 1997;3:2493-500.
18. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, chalky count and computer image analysis. J Pathol 1995;177:275-83.
19. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-24.
20. Novaes M, Bendit I, Garicochea B, del Giglio A. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol 1997;50:209-11.
21. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989;86:2617-21.
22. He Q, Marjamaki M, Soini H, Mertsola J, Viljanen MK. Primers are decisive for sensitivity of PCR. Biotechniques. 1994;17:82-7.
23. Galan M, Vinolas N, Colomer D, Soler G, Munoz M, Longaron R, Ventura PJ, Gascon P, Estape J. Detection of occult breast cancer cells by amplification of CK19 mRNA by reverse transcriptase-polymerase chain reaction: role of surgical manipulation. Anticancer Res 2002;22:2877-84.
24. Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999;17:870-9.
25. Ktuger W, Krzizanowski C, Holweg M, Stockschlader M, Kroger N, Jung R, Mross K, Jonat W, Zander AR. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996;122:679-86.
26. Schoenfeld A, Kruger KH, Gomm J, Sinnett HD, Gazet JC, Sacks N, Bender HG, Luqmani Y, Coombes RC. The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur J Cancer 1997;33:854-61.
27. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis CH, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulis V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002;20:3404-12.
28. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 2003;14:849-55.
29. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995;346:1334-5.
30. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997;89:1044-9.
31. Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S, Sugimachi K. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 1998;4:2129-34.
32. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
33. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 2000;4:403-5.
34. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000;6:139-46.
35. Viens P, Jacquemier J, Bardou VJ, Bertucci F, Penault-Llorca F, Puig B, Gravis G, Oziel-Taieb S, Resbeut M, Houvenaeghel G, Camerlo J, Birbaum D, et al. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat 1999;54:205-12.
36. Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenae ghel GF, Geneix JA, Puig BD, Bardou VJ, Hassoun JA, Birnbaum D, Viens PJ. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol 1998;184:130-5.
37. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-6.
38. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18:80-6.
39. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
40. Deplanque G, Harris AL. Anti-angiogenic agents: clinical trial design and therapies in development. Eur J Cancer 2000;36:1713-24.
41. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
42. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
43. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460-9.
44. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000;89:51-62.
45. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
46. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
47. Koukourakis MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, Retalis G, Georgoulias V. Tumor and Angiogenesis Research Group. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 2002;52:144-55.